Beneficial Ownership Report · SCHEDULE 13G
Crescent Biopharma, Inc.
CBIONASDAQEQUITYCurrent
Beneficial Ownership Report
Structured filing — SCHEDULE 13G
primary_doc.xml
Subject company
- Company
- CRESCENT BIOPHARMA INC
- Company CIK
- 0001253689
- Street
- 300 FIFTH AVENUE
- City
- Waltham
- State / country code
- MA
- Postal code
- 02451
Statement details
- Security class
- Common Stock
- Event date
- 09/30/2026
- Rule designation
- Rule 13d-1(b)
Reporting person 1
- Name
- BlackRock, Inc.
- Citizenship / organization
- DE
- Reporting person type
- HC
- Group designation
- b
- Aggregate amount owned
- 2,075,291
- Percent of class
- 5.6
- Sole voting power
- 2,034,925
- Shared voting power
- 0
- Sole dispositive power
- 2,075,291
- Shared dispositive power
- 0
Item 1
Issuer
CRESCENT BIOPHARMA INC
Principal executive office address
300 FIFTH AVENUE Waltham MA 02451
Item 2
Citizenship
See Item 4 of Cover Page
Filing person
BlackRock, Inc. In accordance with SEC Release No. 34-39538 (January 12, 1998), this Schedule 13G reflects the securities beneficially owned, or deemed to be beneficially owned, by certain business units (collectively, the "Reporting Business Units") of BlackRock, Inc. and its subsidiaries and affiliates. It does not include securities, if any, beneficially owned by other business units whose beneficial ownership of securities are disaggregated from that of the Reporting Business Units in accordance with such release.
Principal business or residence address
BlackRock, Inc., 50 Hudson Yards New York, NY 10001
Item 3
Not applicable indication
N
Type of filing person
HC
Item 4
Percent of class
5.6
Amount beneficially owned
2075291
Sole voting power
2034925
Shared voting power
0
Sole dispositive power
2075291
Shared dispositive power
0
Item 5
Not applicable indication
Y
Ownership of 5% or less
N
Item 6
Not applicable indication
N
Ownership on behalf of another person
Various persons have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of the common stock of CRESCENT BIOPHARMA INC. No one person's interest in the common stock of CRESCENT BIOPHARMA INC is more than five percent of the total outstanding common shares.
Item 7
Not applicable indication
N
Subsidiaries
See Exhibit 99
Item 8
Not applicable indication
Y
Item 9
Not applicable indication
Y
Item 10
Not applicable indication
N
Certifications
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
Exhibits
Exhibit 24: Power of Attorney Exhibit 99: Item 7
Signature 1
- Reporting person
- BlackRock, Inc.
- Signed
- Spencer Fleming
- Title
- Managing Director
- Date
- 10/27/2026
Filed exhibits
- EXHIBIT 24: POWER OF ATTORNEY ↗PowerOfAttorney.txt
- EXHIBIT 99: ITEM 7 ↗Item_7.txt
Company context
GlycoMimetics is a late clinical-stage biotechnology company that was previously discovering and developing glycobiology-based therapies for cancers, including AML, and for inflammatory diseases. The company’s scientific approach was based on an understanding of the role that carbohydrates play in cell recognition. Its specialized chemistry platform can be used to discover small molecule drugs, known as glycomimetics, that alter carbohydrate-mediated recognition in diverse disease states, including cancers and inflammation. The company’s goal was to develop transformative therapies for diseases with high unmet medical need. Learn more at www.glycomimetics.com.